Sanctuary Advisors LLC Purchases 6,474 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Sanctuary Advisors LLC grew its position in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 36.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,433 shares of the company’s stock after purchasing an additional 6,474 shares during the quarter. Sanctuary Advisors LLC’s holdings in 10x Genomics were worth $368,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. Capital Performance Advisors LLP bought a new position in 10x Genomics during the 3rd quarter worth approximately $35,000. Venturi Wealth Management LLC grew its position in 10x Genomics by 1,108.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company’s stock worth $55,000 after acquiring an additional 2,240 shares during the last quarter. First Horizon Advisors Inc. grew its position in 10x Genomics by 53.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 2,910 shares of the company’s stock worth $66,000 after acquiring an additional 1,012 shares during the last quarter. Blue Trust Inc. grew its position in 10x Genomics by 73.1% during the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock worth $44,000 after acquiring an additional 1,299 shares during the last quarter. Finally, KBC Group NV grew its position in 10x Genomics by 38.8% during the 3rd quarter. KBC Group NV now owns 3,225 shares of the company’s stock worth $73,000 after acquiring an additional 902 shares during the last quarter. 84.68% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

TXG has been the topic of several recent research reports. JPMorgan Chase & Co. reduced their price target on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Thursday, February 13th. Canaccord Genuity Group cut their price objective on 10x Genomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of 10x Genomics in a research report on Wednesday, February 19th. Leerink Partnrs lowered 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 13th. Finally, Leerink Partners lowered 10x Genomics from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $25.00 to $12.00 in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $20.57.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, insider Benjamin J. Hindson sold 4,573 shares of 10x Genomics stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $50,623.11. Following the completion of the transaction, the insider now owns 335,324 shares in the company, valued at approximately $3,712,036.68. The trade was a 1.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Serge Saxonov sold 5,092 shares of 10x Genomics stock in a transaction on Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $56,368.44. Following the transaction, the chief executive officer now owns 879,482 shares of the company’s stock, valued at $9,735,865.74. The trade was a 0.58 % decrease in their position. The disclosure for this sale can be found here. 10.03% of the stock is owned by company insiders.

10x Genomics Stock Down 7.9 %

TXG opened at $9.85 on Tuesday. The stock has a market cap of $1.20 billion, a PE ratio of -6.48 and a beta of 1.85. The business has a 50 day moving average of $13.90 and a 200-day moving average of $16.67. 10x Genomics, Inc. has a 52 week low of $9.77 and a 52 week high of $45.60.

10x Genomics (NASDAQ:TXG) last released its earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. Equities analysts anticipate that 10x Genomics, Inc. will post -1.43 EPS for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.